Supreme Court to decide whether federal law preempts Roundup failure-to-warn suits against Bayer
- Bayer AG, which bought Monsanto in 2018, is appealing a Missouri $1.25M verdict over Roundup warnings.
- Missouri appeals and state supreme court actions prompted Bayer to seek U.S. Supreme Court intervention.
- A Supreme Court win for Bayer could curtail state tort claims and lessen its nationwide liability exposure.
Supreme Court to resolve Roundup preemption fight
The U.S. Supreme Court is agreeing to hear Monsanto Co. v. Durnell on April 27, setting up a high-stakes test of whether federal pesticide labeling law preempts state failure-to-warn claims over the weedkiller Roundup. Bayer AG, which purchased Monsanto in 2018, is appealing a Missouri jury verdict that awarded plaintiff John Durnell $1.25 million after a jury found Monsanto failed to warn him that exposure to Roundup, which contains glyphosate, could have contributed to his non‑Hodgkin lymphoma. A state appeals court upheld the liability ruling and the Missouri Supreme Court declined review, prompting Bayer to seek intervention at the national level.
At the heart of the appeal is a federal preemption argument: Monsanto contends the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) and EPA-approved labeling decisions occupy the field, barring state juries from imposing inconsistent warnings. The U.S. Solicitor General D. John Sauer files a brief siding with Monsanto, warning the court that allowing the Missouri decision to stand could invite juries to second‑guess science-based agency determinations. Plaintiffs’ lawyers counter that Monsanto “has known for decades” about glyphosate risks and marketed Roundup as safe, framing the case as a traditional product-liability dispute about corporate warnings rather than a challenge to federal regulatory judgments.
The Supreme Court’s ruling could reshape liability exposure for Bayer and others in the agrochemical industry by limiting state-court avenues for mass tort claims and steering more disputes into the administrative and federal statutory framework. Thousands of Roundup suits are pending nationwide, and the decision may affect how courts treat scientific assessments by agencies like the EPA versus evidence presented in state tort trials. A win for Bayer would bolster the argument that pesticide safety questions belong primarily to federal regulators; a loss would preserve a broad path for state-law claims and sustain pressure on manufacturers regarding warning disclosures and risk communication.
Science disputes heighten regulatory and legal pressure
The litigation unfolds against conflicting assessments: the World Health Organization’s cancer agency classifies glyphosate as “probably carcinogenic to humans,” while the U.S. EPA has rejected that finding and California listed glyphosate as a carcinogen in 2017. Those divergent positions complicate the legal debate over whether federal regulatory conclusions should preempt state liability claims.
Justices also take up privacy and administrative-law cases
The court schedules other high-profile arguments the same term, including Chatrie v. United States on cellphone location‑history warrants and consolidated FCC v. AT&T and Verizon v. FCC on whether in‑house FCC adjudications and penalties conform with the Communications Act, signaling a term that weighs heavily on administrative authority and individual privacy.
Related Cashu News

Bristol-Myers Squibb's Reclassification Enhances Growth Potential in Defensive Investment Strategy
Bristol-Myers Squibb Company (Ticker: BMY) undergoes a key reclassification across the Russell indexes, marking a transformative moment for the company. Moving to the Russell 1000 Defensive and Russel…

Vertex Pharmaceuticals' Casgevy Gains FDA Approval for Expanded Sickle Cell Disease Treatment Options
Vertex Pharmaceuticals (Ticker: VRTX) receives a significant boost in its ongoing battle against sickle cell disease with the recent FDA approval of an expanded label for its gene therapy product, Cas…

Gilead Sciences Gains FDA Approval for Trodelvy in First-Line Triple-Negative Breast Cancer Treatment
Gilead Sciences (Ticker: GILD) makes significant strides in oncology therapy with the recent approval of its drug Trodelvy for patients with unresectable or metastatic triple-negative breast cancer. T…

Merck Advances HIV Treatment and Faces Regulatory Scrutiny Amidst Market Success
Merck & Co. (Ticker: MRK) has recently made significant strides in the pharmaceutical landscape, particularly with its advancements in HIV treatment. The company's innovative drug, IDVYNSO, has receiv…